Press Releases Year: - Any -201920182017201620152014 Items per page 102550 Date Title and Summary Additional Formats Toggle SummaryJun 11, 2014 Alder BioPharmaceuticals to Present at Two Conferences in June View HTML Alder BioPharmaceuticals to Present at Two Conferences in June 16.1 KB Toggle SummaryJun 18, 2014 Alder BioPharmaceuticals Reports First Quarter 2014 Financial Results View HTML Alder BioPharmaceuticals Reports First Quarter 2014 Financial Results 20.6 KB Toggle SummaryJun 26, 2014 Data From Proof-of-Concept Clinical Trial of ALD403, a Monoclonal Antibody Against CGRP for the Prevention of Migraine, to be Presented at 56th Annual Scientific Meeting of the American Headache Society View HTML Data From Proof-of-Concept Clinical Trial of ALD403, a Monoclonal Antibody Against CGRP for the Prevention of Migraine, to be Presented at 56th Annual Scientific Meeting of the American Headache Society 17.8 KB Toggle SummaryJun 27, 2014 Alder BioPharmaceuticals Added to Russell 3000(R) Index View HTML Alder BioPharmaceuticals Added to Russell 3000(R) Index 14.5 KB Toggle SummaryJul 29, 2014 Alder BioPharmaceuticals to Host Conference Call to Discuss Second Quarter 2014 Financial and Operating Results View HTML Alder BioPharmaceuticals to Host Conference Call to Discuss Second Quarter 2014 Financial and Operating Results 14 KB Toggle SummaryAug 05, 2014 Alder BioPharmaceuticals Reports Second Quarter 2014 Financial and Operating Results View HTML Alder BioPharmaceuticals Reports Second Quarter 2014 Financial and Operating Results 25.9 KB Toggle SummarySep 02, 2014 Alder BioPharmaceuticals Regains Worldwide Rights to Clazakizumab View HTML Alder BioPharmaceuticals Regains Worldwide Rights to Clazakizumab 20.9 KB Toggle SummaryOct 06, 2014 Data From Alder BioPharmaceuticals' Proof-of-Concept Clinical Trial of ALD403 Published in Lancet Neurology Demonstrates ALD403 Effective in the Preventive Treatment of Migraine View HTML Data From Alder BioPharmaceuticals' Proof-of-Concept Clinical Trial of ALD403 Published in Lancet Neurology Demonstrates ALD403 Effective in the Preventive Treatment of Migraine 19.5 KB Toggle SummaryOct 24, 2014 Alder BioPharmaceuticals to Host Conference Call to Discuss Third Quarter 2014 Financial and Operating Results View HTML Alder BioPharmaceuticals to Host Conference Call to Discuss Third Quarter 2014 Financial and Operating Results 14.2 KB Toggle SummaryNov 03, 2014 Alder BioPharmaceuticals Initiates Phase 2b Clinical Trial of ALD403 for Preventative Treatment of Chronic Migraine View HTML Alder BioPharmaceuticals Initiates Phase 2b Clinical Trial of ALD403 for Preventative Treatment of Chronic Migraine 26.7 KB Pagination Current page 1 Page 2 Page 3 Page 4 … Next page Next Last page Last
Data From Proof-of-Concept Clinical Trial of ALD403, a Monoclonal Antibody Against CGRP for the Prevention of Migraine, to be Presented at 56th Annual Scientific Meeting of the American Headache Society 17.8 KB
Alder BioPharmaceuticals to Host Conference Call to Discuss Second Quarter 2014 Financial and Operating Results 14 KB
Data From Alder BioPharmaceuticals' Proof-of-Concept Clinical Trial of ALD403 Published in Lancet Neurology Demonstrates ALD403 Effective in the Preventive Treatment of Migraine 19.5 KB
Alder BioPharmaceuticals to Host Conference Call to Discuss Third Quarter 2014 Financial and Operating Results 14.2 KB
Alder BioPharmaceuticals Initiates Phase 2b Clinical Trial of ALD403 for Preventative Treatment of Chronic Migraine 26.7 KB
